In a filing, Cogent Biosciences Inc revealed its Chief Commercial Officer Pinnow Cole acquired Company’s shares for reported $0.33 million on Jan 14 ’25. In the deal valued at $7.60 per share,43,750 shares were bought. As a result of this transaction, Pinnow Cole now holds 45,848 shares worth roughly $0.32 million.
Scotiabank initiated its Cogent Biosciences Inc [COGT] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $17. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in mid December from “a Buy” to “a Hold”. Robert W. Baird also remained covering COGT and has decreased its forecast on February 26, 2024 with a “Neutral” recommendation from previously “an Outperform” rating. Citigroup started covering the stock on February 08, 2024. It rated COGT as “a Buy”.
Price Performance Review of COGT
On Friday, Cogent Biosciences Inc [NASDAQ:COGT] saw its stock fall -5.40% to $7.01. Over the last five days, the stock has lost -6.91%. Cogent Biosciences Inc shares have fallen nearly -10.13% since the year began. Nevertheless, the stocks have fallen -0.28% over the past one year. While a 52-week high of $12.61 was reached on 01/30/25, a 52-week low of $5.73 was recorded on 02/26/25. SMA at 50 days reached $8.09, while 200 days put it at $9.27.
Levels Of Support And Resistance For COGT Stock
The 24-hour chart illustrates a support level at 6.78, which if violated will result in even more drops to 6.55. On the upside, there is a resistance level at 7.36. A further resistance level may holdings at 7.71. The Relative Strength Index (RSI) on the 14-day chart is 39.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.08, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.91%. Stochastics %K at 44.79% indicates the stock is a holding.
